Skip to main content
NACFC 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session
Back

PHARM
Thematic Poster Session

TPS01--Pharmacotherapy

Thursday, September 26, 2024
10:15 AM – 11:45 AM ET
Location:Theater A (Exhibit & Poster Hall)

This session consists of two main parts: poster viewing followed by a moderated discussion. It is designed to engage the authors and the audience in a discussion that ties together ideas from multiple pharmacy-related posters in the session. Topics will include adverse events and occurrence of behavioral disorders in pediatric patients on ETI, pharmacokinetics (PK) and pharmacogenomics of ETI, prevalence of cannabidiol use, model informed tobramycin dosing, PK of omadacycline, hybrid telehealth pharmacist visits, and medication access.

Learning Objectives:

  • Examine current pharmacy services and telemedicine practices
  • Review updates for omadacycline, tobramycin, and cannabidiol
  • Describe pharmacokinetics of ETI and real-world effects of ETI in ages 2-5 years old

Presentations:

  • 10:15 AM – 11:45 AM ET
    Prevalence of Cannabidiol use in Persons with Cystic Fibrosis 

    Speaker: Emma M. Tillman, PharmD, PhD (she/her/hers) – Indiana Unversity

  • 10:15 AM – 11:45 AM ET
    Asynchronous, hybrid telemedicine clinical pharmacist visits as part of pediatric cystic fibrosis care

    Speaker: Hanna Phan, PharmD, FCCP, FPPA (she/her/hers) – University of Michigan

  • 10:15 AM – 11:45 AM ET
    Adverse events in people with cystic fibrosis aged 2-5 years old receiving elexacaftor/tezacaftor/ivacaftor

    Speaker: Rebecca S. Pettit, PharmD, MBA, BCPS, BCPPS, FCCP (she/her/hers) – Riley Hospital for Children at IU Health

  • 10:15 AM – 11:45 AM ET
    Pharmacogenomic variation influences elexcaftor/tezacaftor/ivacaftor concentrations in people with cystic fibrosis

    Speaker: Cameron J. McKinzie, PharmD, BCPPS, BCPS, CPP (she/her/hers) – UNC Medical Center

  • 10:15 AM – 11:45 AM ET
    Mental health diagnosis and medication changes after initiation of elexacaftor/tezacaftor/ivacaftor

    Speaker: Cameron J. McKinzie, PharmD, BCPPS, BCPS, CPP (she/her/hers) – UNC Medical Center

  • 10:15 AM – 11:45 AM ET
    Hitting the target: model-informed precision dosing of tobramycin in pediatric patients with cystic fibrosis

    Speaker: Jake Brockmeyer, PharmD (he/him/his) – Stanford Medicine Children's Health

  • 10:15 AM – 11:45 AM ET
    Enhancing medication access in an adult cystic fibrosis outpatient clinic through the integration of a Certified Pharmacy Technician

    Speaker: Kelly Leal, CPhT-Adv (she/her/hers) – UofL Health Adult Cystic Fibrosis Center

  • 10:15 AM – 11:45 AM ET
    Pharmacokinetics of omadacycline in adults with cystic fibrosis

    Speaker: Madeline Sanders (she/her/hers) – University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences

  • 10:15 AM – 11:45 AM ET
    Elexacaftor/tezacaftor/ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis

    Speaker: Ngoc Hoa Truong (he/him/his) – URP7323, Pharmacologie Et Évaluation Des Thérapeutiques Chez L'enfant Et La Femme Enceinte Université Paris Cité, Paris, France.

  • 10:15 AM – 11:45 AM ET
    Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurrence of behavioral disorders in children aged 2 to 5 years old

    Speaker: Ngoc Hoa Truong (he/him/his) – URP7323, Pharmacologie Et Évaluation Des Thérapeutiques Chez L'enfant Et La Femme Enceinte Université Paris Cité, Paris, France.